Thelansis

 Recurrent vulvovaginal candidiasis (RVVC), usually defined as four or more episodes of symptomatic VVC within 1 year, affects a small percentage of women (<5%). The pathogenesis of RVVC is poorly understood, and most women with RVVC have no apparent predisposing or underlying conditions. C. glabrata and other nonalbicans Candida species are observed in 10%–20% of women with RVVC. According to Thelansis disease modeling data and systematic literature review, the prevalence of RVVC is ~5% to 12% in the US and Europe. Thelansis’s “Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis (RVVC) treatment modaliti...